Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-17T04:11:10.515Z Has data issue: false hasContentIssue false

Ofloxacin

Published online by Cambridge University Press:  21 June 2016

Allan R. Tunkel*
Affiliation:
Department of Internal Medicine (Infectious Diseases), Medical College of Pennsylvania, Philadelphia, Pennsylvania
W. Michael Scheld
Affiliation:
Departments of Internal Medicine (Infectious Diseases) and Neurosurgery, The University of Virginia Health Sciences Center, Charlottesville, Virginia
*
Division of Infectious Diseases, Medical College of Pennsylvania, 3300 Henry Ave., Philadelphia, PA 19129

Extract

The fluoroquinolone antibiotic agents have been a major advance in the treatment of bacterial infections. The original quinolone nalidixic acid suffered from a narrow spectrum of activity and rapid development of drug resistance. The newer fluoroquinolones have more desirable properties including good oral absorption, enhanced antimicrobial activity, improved pharmacokinetic profile, and limited adverse effects. These improvements are the results of two structural modifications: addition of a fluorine atom at position 6; and addition of a piperazyl moiety at position 7 of the bicyclic nucleus. The three fluoroquinolones currently available in the United States are norfloxacin, ciprofloxacin, and ofloxacin. This review focuses on ofloxacin, the newly licensed agent, emphasizing the salient features of the drug and specific indications for use.

Information

Type
Clinical Pharmacology of Antibiotics
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1991 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable